Patrick McDonald
Community Health · Aberdeen, MDNPI 1215284815
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,097 and has fallen 89.6% since, to $114 in 2025.
Across 171 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$482
- Neurocrine Biosciences, Inc.$434
- Alkermes, Inc.$370
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$327
- Supernus Pharmaceuticals, Inc.$301
- Sunovion Pharmaceuticals Inc.$288
- plus $1K from 10 others
What the payments were for
- Food & beverage$3,53199%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 24 | $482 |
| Neurocrine Biosciences, Inc. | 20 | $434 |
| Alkermes, Inc. | 17 | $370 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $327 |
| Supernus Pharmaceuticals, Inc. | 11 | $301 |
| Sunovion Pharmaceuticals Inc. | 14 | $288 |
| AbbVie | 13 | $267 |
| Vanda Pharmaceuticals Inc. | 8 | $213 |
| Ironshore Pharmaceuticals Inc. | 9 | $185 |
| Tris Pharma Inc | 14 | $176 |
| Lundbeck LLC | 9 | $170 |
| Teva Pharmaceuticals USA, Inc. | 8 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $132 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$144
How this compares
Too few community health providers in Marylandto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 12 | $297 |
| Hydroxyzine Hcl | 13 | $29 |
| Fluoxetine Hcl | 15 | $17 |
Paid to pharmacies, not to this prescriber.
Other community health in Aberdeen
- Teresa WoodwardBel Air$135
- Nicole BrownTowson$36
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.